Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab

Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute of Medical Sciences and Nutrition Salvador Zubirán, shared a post on X:

“How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab?

Lack of evidence and need trials
Look at proposed algorithm
Ongoing trials mUC after EV and ICIs
Table of efficacy outcomes of platinum, erdafitinib (FGFR3) and trastu deruxtecan.”

“Optimizing Treatment Strategies for Advanced Urothelial Cancer: What Comes After Frontline Enfortumab Vedotin and Pembrolizumab?”

Authors: Maria Bourlon, Paola Valdez, Thomas Powles, Thomas Flaig.

Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab